U.S. Markets closed

Eli Lilly and Company (LLY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
83.04-1.24 (-1.47%)
At close: 4:00PM EDT

83.04 0.00 (0.00%)
After hours: 5:57PM EDT

People also watch
BMYMRKABTGSKJNJ
Full screen
Previous Close84.28
Open84.18
Bid0.00 x
Ask0.00 x
Day's Range83.04 - 84.33
52 Week Range64.18 - 86.72
Volume2,365,826
Avg. Volume3,883,353
Market Cap87.35B
Beta0.18
PE Ratio (TTM)40.15
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (2.48%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
    Motley Fool5 hours ago

    Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.

    Find out which of these pharmaceutical stocks is the best pick right now.

  • This Biotech Crashed 28% Despite Positive Migraine Drug Tests
    Investor's Business Daily7 hours ago

    This Biotech Crashed 28% Despite Positive Migraine Drug Tests

    Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.

  • Barrons.com7 hours ago

    [$$] Merck Cholesterol Drug Could Help Unlock Value

    In the last decade, no fewer than three major pharmaceutical companies have suffered defeat trying to bring a new class of cholesterol-lowering medication to market.s Much to the surprise of investors, Merck & Co. (MRK) could succeed where Pfizer (PFE), Roche (RHHBY) and Eli Lilly & Co. (LLY) have all failed. Merck has yet to decide if it will seek Food and Drug Administration approval, a sign to some that the company isn’t sure if the study data, though positive, are strong enough to ensure regulatory approval. Thanks to the growing success of Merck’s immunotherapy cancer drug Keytruda, the shares have gained 19% in the past year to near a 52-week high of $66.80.